Related Experiment Video

Updated: Aug 14, 2025

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

10.9K

Improving Risk Stratification for Patients With Type 2 Myocardial Infarction

Caelan Taggart1, Karla Monterrubio-Gómez2, Andreas Roos3

  • 1BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Journal of the American College of Cardiology
|January 11, 2023
PubMed

Insights

A new T2-risk score effectively predicts major adverse cardiovascular events in type 2 myocardial infarction patients. This validated tool aids clinicians in prognostication and targeted therapy, improving cardiovascular outcomes.

Area of Science:

  • Cardiology
  • Clinical Risk Stratification
  • Myocardial Infarction Research

Background:

  • Type 2 myocardial infarction (T2MI) is associated with poor cardiovascular outcomes.
  • Currently, no validated risk stratification tools exist to guide T2MI management.
  • Effective risk assessment is crucial for timely intervention and improved patient prognosis.

Purpose of the Study:

  • To develop and validate a risk stratification tool for predicting adverse outcomes in T2MI patients.
  • The study aimed to create the T2-risk score for identifying high-risk individuals.
  • To improve the management and outcomes of patients with type 2 myocardial infarction.

Main Methods:

  • The T2-risk score was derived from a prospective multicenter cohort of T2MI patients.
  • Cox proportional hazards models identified key predictors for myocardial infarction or death at 1 year.
  • Validation was performed in independent single-center and multicenter cohorts.

Main Results:

  • The T2-risk score demonstrated good discrimination (AUC: 0.76) and calibration for predicting 1-year adverse events.
  • Performance was consistent across derivation and validation cohorts (AUCs: 0.83 and 0.74).
  • The T2-risk score outperformed the GRACE 2.0 score in predicting outcomes in T2MI patients.

Conclusions:

  • The T2-risk score is a validated tool for prognostication in T2MI patients.
  • It can assist clinicians in targeting investigations and preventative therapies effectively.
  • The score performs well across diverse healthcare settings, enhancing clinical decision-making for T2MI.
Abstract

Keywords:
risk predictiontype 2 myocardial infarction

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.6K
Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

28.1K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
30
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
28
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
14
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
20
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19